Compare Regeneron Pharmaceuticals Inc (REGN) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while YieldMax TSLA Option Income Strategy ETF trades at $22.48. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while YieldMax TSLA Option Income Strategy ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| REGN | TSLY | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $852.03 | $48.25 |
52-Week Low | $555.51 | $20.49 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
TSLY trades at $22.79, up 3.17% with a bullish technical signal despite bearish moving averages. The ETF maintains consistent weekly dividend distributions ranging from $0.18 to $0.28, though recent analysis highlights concerns about underperformance relative to Tesla's underlying stock. Technical indicators show neutral oscillators with RSI at 59.70, while support and resistance cluster around $22-$24 levels.
The outlook remains mixed with high yield appeal offset by structural limitations in capturing Tesla's upside. Key risks include volatility dependency and capped growth potential. Investors face the trade-off between income generation and capital appreciation in this option-income strategy ETF.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
